Compare NXT & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXT | WST |
|---|---|---|
| Founded | 2013 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 18.5B |
| IPO Year | 2023 | 2004 |
| Metric | NXT | WST |
|---|---|---|
| Price | $125.74 | $326.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 7 |
| Target Price | $115.67 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 1.5M | 879.7K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | ★ 2.97 | 1.49 |
| EPS | ★ 2.86 | 1.92 |
| Revenue | ★ $2,959,197,000.00 | $2,886,900,000.00 |
| Revenue This Year | $19.76 | $6.76 |
| Revenue Next Year | $11.96 | $6.22 |
| P/E Ratio | ★ $42.48 | $168.14 |
| Revenue Growth | ★ 18.38 | 1.95 |
| 52 Week Low | $51.69 | $203.74 |
| 52 Week High | $131.72 | $323.63 |
| Indicator | NXT | WST |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 78.60 |
| Support Level | $111.35 | $234.43 |
| Resistance Level | $128.86 | N/A |
| Average True Range (ATR) | 7.38 | 9.23 |
| MACD | 0.94 | 2.49 |
| Stochastic Oscillator | 81.05 | 99.29 |
Nextpower (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextpower's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextpower has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.